Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CKS1B drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CKS1B Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for PPI screening. |
View CKS1B Products |
| Gene Delivery | CKS1B Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression validation. |
View CKS1B Products |
| Benchmark Ab | Anti-CKS1B Recombinant Antibody Recombinant positive control for Western Blot and ELISA assays. |
View CKS1B Products |
| Validator | CKS1B siRNA Set For knockdown verification and functional rescue assays. |
View CKS1B Products |
| Related Target A | SKP2 Direct binding partner in the SCF-Skp2-Cks1 ubiquitin ligase complex. |
View SKP2 Products |
| Related Target B | CDKN1B Also known as p27(Kip1), the downstream target substrate regulated by CKS1B. |
View CDKN1B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CKS1B-Skp2 Protein-Protein Interaction (PPI) Screen | High-purity, monomeric recombinant proteins with verified binding sequences. |
| Selectivity over CKS2 Homolog | Homolog panel proteins (CKS1B vs. CKS2) strictly verified by mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies and validation-grade reagents included |
| False Positives in Small Molecule Screens | Validated siRNA sets included for target-specific knockdown controls |
Live CKS1B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CKS1B therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum proteasome inhibitors to targeted Protein-Protein Interaction (PPI) inhibitors and PROTACs. As first-generation therapies targeting the cell cycle reach clinical maturity, the next wave of R&D is targeting the CKS1B-Skp2-p27 axis to overcome drug resistance in hematological malignancies and solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI | Academic Institutes, Biotech Startups | Multiple Myeloma, Breast Cancer | CKS1B-Skp2 binding assay (Need high-purity, active recombinant proteins) |
| PROTAC / Degrader | Targeted Protein Degradation (TPD) Companies | Refractory Solid Tumors | Ternary complex formation assay (Need sequence-verified CKS1B and SKP2) |
| Combination Therapy | Global Pharma | Bortezomib-resistant Myeloma | In vitro validation (Need validated siRNA and ORF overexpression tools) |